BACKGROUND: Twenty-one states have laws requiring that women be notified if they have dense breasts and that they be advised to discuss supplemental imaging with their provider. OBJECTIVE: To better direct discussions of supplemental imaging by determining which combinations of breast cancer risk and Breast Imaging Reporting and Data System (BI-RADS) breast density categories are associated with high interval cancer rates. DESIGN: Prospective cohort. SETTING: Breast Cancer Surveillance Consortium (BCSC) breast imaging facilities. PATIENTS: 365,426 women aged 40 to 74 years who had 831,455 digital screening mammography examinations. MEASUREMENTS: BI-RADS breast density, BCSC 5-year breast cancer risk, and interval cancer rate (invasive cancer ≤12 months after a normal mammography result) per 1000 mammography examinations. High interval cancer rate was defined as more than 1 case per 1000 examinations. RESULTS: High interval cancer rates were observed for women with 5-year risk of 1.67% or greater and extremely dense breasts or 5-year risk of 2.50% or greater and heterogeneously dense breasts (24% of all women with dense breasts). The interval rate of advanced-stage disease was highest (>0.4 case per 1000 examinations) among women with 5-year risk of 2.50% or greater and heterogeneously or extremely dense breasts (21% of all women with dense breasts). Five-year risk was low to average (0% to 1.66%) for 51.0% of women with heterogeneously dense breasts and 52.5% with extremely dense breasts, with interval cancer rates of 0.58 to 0.63 and 0.72 to 0.89 case per 1000 examinations, respectively. LIMITATION: The benefit of supplemental imaging was not assessed. CONCLUSION: Breast density should not be the sole criterion for deciding whether supplemental imaging is justified because not all women with dense breasts have high interval cancer rates. BCSC 5-year risk combined with BI-RADS breast density can identify women at high risk for interval cancer to inform patient-provider discussions about alternative screening strategies. PRIMARY FUNDING SOURCE: National Cancer Institute.
BACKGROUND: Twenty-one states have laws requiring that women be notified if they have dense breasts and that they be advised to discuss supplemental imaging with their provider. OBJECTIVE: To better direct discussions of supplemental imaging by determining which combinations of breast cancer risk and Breast Imaging Reporting and Data System (BI-RADS) breast density categories are associated with high interval cancer rates. DESIGN: Prospective cohort. SETTING:Breast Cancer Surveillance Consortium (BCSC) breast imaging facilities. PATIENTS: 365,426 women aged 40 to 74 years who had 831,455 digital screening mammography examinations. MEASUREMENTS: BI-RADS breast density, BCSC 5-year breast cancer risk, and interval cancer rate (invasive cancer ≤12 months after a normal mammography result) per 1000 mammography examinations. High interval cancer rate was defined as more than 1 case per 1000 examinations. RESULTS:High interval cancer rates were observed for women with 5-year risk of 1.67% or greater and extremely dense breasts or 5-year risk of 2.50% or greater and heterogeneously dense breasts (24% of all women with dense breasts). The interval rate of advanced-stage disease was highest (>0.4 case per 1000 examinations) among women with 5-year risk of 2.50% or greater and heterogeneously or extremely dense breasts (21% of all women with dense breasts). Five-year risk was low to average (0% to 1.66%) for 51.0% of women with heterogeneously dense breasts and 52.5% with extremely dense breasts, with interval cancer rates of 0.58 to 0.63 and 0.72 to 0.89 case per 1000 examinations, respectively. LIMITATION: The benefit of supplemental imaging was not assessed. CONCLUSION: Breast density should not be the sole criterion for deciding whether supplemental imaging is justified because not all women with dense breasts have high interval cancer rates. BCSC 5-year risk combined with BI-RADS breast density can identify women at high risk for interval cancer to inform patient-provider discussions about alternative screening strategies. PRIMARY FUNDING SOURCE: National Cancer Institute.
Authors: Virginia L Ernster; Rachel Ballard-Barbash; William E Barlow; Yingye Zheng; Donald L Weaver; Gary Cutter; Bonnie C Yankaskas; Robert Rosenberg; Patricia A Carney; Karla Kerlikowske; Stephen H Taplin; Nicole Urban; Berta M Geller Journal: J Natl Cancer Inst Date: 2002-10-16 Impact factor: 13.506
Authors: Bonnie C Yankaskas; Stephen H Taplin; Laura Ichikawa; Berta M Geller; Robert D Rosenberg; Patricia A Carney; Karla Kerlikowske; Rachel Ballard-Barbash; Gary R Cutter; William E Barlow Journal: Radiology Date: 2005-02 Impact factor: 11.105
Authors: R Ballard-Barbash; S H Taplin; B C Yankaskas; V L Ernster; R D Rosenberg; P A Carney; W E Barlow; B M Geller; K Kerlikowske; B K Edwards; C F Lynch; N Urban; C A Chrvala; C R Key; S P Poplack; J K Worden; L G Kessler Journal: AJR Am J Roentgenol Date: 1997-10 Impact factor: 3.959
Authors: Celine M Vachon; V Shane Pankratz; Christopher G Scott; Lothar Haeberle; Elad Ziv; Matthew R Jensen; Kathleen R Brandt; Dana H Whaley; Janet E Olson; Katharina Heusinger; Carolin C Hack; Sebastian M Jud; Matthias W Beckmann; Ruediger Schulz-Wendtland; Jeffrey A Tice; Aaron D Norman; Julie M Cunningham; Kristen S Purrington; Douglas F Easton; Thomas A Sellers; Karla Kerlikowske; Peter A Fasching; Fergus J Couch Journal: J Natl Cancer Inst Date: 2015-03-04 Impact factor: 13.506
Authors: P L Porter; A Y El-Bastawissi; M T Mandelson; M G Lin; N Khalid; E A Watney; L Cousens; D White; S Taplin; E White Journal: J Natl Cancer Inst Date: 1999-12-01 Impact factor: 13.506
Authors: Edward A Sickles; Diana L Miglioretti; Rachel Ballard-Barbash; Berta M Geller; Jessica W T Leung; Robert D Rosenberg; Rebecca Smith-Bindman; Bonnie C Yankaskas Journal: Radiology Date: 2005-06 Impact factor: 11.105
Authors: Patricia A Carney; Diana L Miglioretti; Bonnie C Yankaskas; Karla Kerlikowske; Robert Rosenberg; Carolyn M Rutter; Berta M Geller; Linn A Abraham; Steven H Taplin; Mark Dignan; Gary Cutter; Rachel Ballard-Barbash Journal: Ann Intern Med Date: 2003-02-04 Impact factor: 25.391
Authors: Brian L Sprague; Ronald E Gangnon; Veronica Burt; Amy Trentham-Dietz; John M Hampton; Robert D Wellman; Karla Kerlikowske; Diana L Miglioretti Journal: J Natl Cancer Inst Date: 2014-09-12 Impact factor: 13.506
Authors: Karla Kerlikowske; Annette Molinaro; Imok Cha; Britt-Marie Ljung; Virginia L Ernster; Kim Stewart; Karen Chew; Dan H Moore; Fred Waldman Journal: J Natl Cancer Inst Date: 2003-11-19 Impact factor: 13.506
Authors: Jeanne S Mandelblatt; Natasha K Stout; Clyde B Schechter; Jeroen J van den Broek; Diana L Miglioretti; Martin Krapcho; Amy Trentham-Dietz; Diego Munoz; Sandra J Lee; Donald A Berry; Nicolien T van Ravesteyn; Oguzhan Alagoz; Karla Kerlikowske; Anna N A Tosteson; Aimee M Near; Amanda Hoeffken; Yaojen Chang; Eveline A Heijnsdijk; Gary Chisholm; Xuelin Huang; Hui Huang; Mehmet Ali Ergun; Ronald Gangnon; Brian L Sprague; Sylvia Plevritis; Eric Feuer; Harry J de Koning; Kathleen A Cronin Journal: Ann Intern Med Date: 2016-01-12 Impact factor: 25.391
Authors: Sylvia K Plevritis; Diego Munoz; Allison W Kurian; Natasha K Stout; Oguzhan Alagoz; Aimee M Near; Sandra J Lee; Jeroen J van den Broek; Xuelin Huang; Clyde B Schechter; Brian L Sprague; Juhee Song; Harry J de Koning; Amy Trentham-Dietz; Nicolien T van Ravesteyn; Ronald Gangnon; Young Chandler; Yisheng Li; Cong Xu; Mehmet Ali Ergun; Hui Huang; Donald A Berry; Jeanne S Mandelblatt Journal: JAMA Date: 2018-01-09 Impact factor: 56.272
Authors: Heidi D Nelson; Ellen S O'Meara; Karla Kerlikowske; Steven Balch; Diana Miglioretti Journal: Ann Intern Med Date: 2016-01-12 Impact factor: 25.391
Authors: Melissa Pilewskie; Emily C Zabor; Elizabeth Gilbert; Michelle Stempel; Oriana Petruolo; Debra Mangino; Mark Robson; Maxine S Jochelson Journal: Breast Cancer Res Treat Date: 2019-01-23 Impact factor: 4.872
Authors: Susan H Busch; Jessica R Hoag; Jenerius A Aminawung; Xiao Xu; Ilana B Richman; Pamela R Soulos; Kelly A Kyanko; Cary P Gross Journal: Am J Public Health Date: 2019-03-21 Impact factor: 9.308
Authors: Deirdre A Hill; Jennifer S Haas; Robert Wellman; Rebecca A Hubbard; Christoph I Lee; Jennifer Alford-Teaster; Karen J Wernli; Louise M Henderson; Natasha K Stout; Anna N A Tosteson; Karla Kerlikowske; Tracy Onega Journal: J Gen Intern Med Date: 2017-12-06 Impact factor: 5.128
Authors: Yiwey Shieh; Donglei Hu; Lin Ma; Scott Huntsman; Charlotte C Gard; Jessica W T Leung; Jeffrey A Tice; Celine M Vachon; Steven R Cummings; Karla Kerlikowske; Elad Ziv Journal: Breast Cancer Res Treat Date: 2016-08-26 Impact factor: 4.872